CLBS - カラドリアス・バイオサイエンス (Caladrius Biosciences Inc.) カラドリアス・バイオサイエンス

 CLBSのチャート


 CLBSの企業情報

symbol CLBS
会社名 Caladrius Biosciences Inc (カラドリアス・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Hospital/Nursing Management  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Caladrius Biosciences Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company''s lead product candidate CLBS03 is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient''s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study a Phase II prospective randomized placebo-controlled double-blind clinical trial to evaluate its Treg product candidate CLBS03 in adolescents with recent onset T1D. The Company plans to develop its product candidate CLBS12 in Japan which is an autologous therapy that derives its cells from peripheral blood through apheresis.   カラドリアス・バイオサイエンスは米国のバイオテクノロジ―企業。独自の細胞治療製品の開発に従事し、再生医療分野でのサ―ビスを提供する。虚血に対処するための治療法の開発、急性心筋梗塞後の損傷した心筋を治療、免疫系の不均衡によって引き起こされる疾患を治療、テクノロジ―再生医療プラットフォ―ムなどがある。   Caladrius Biosciences Inc is a biopharmaceutical company. The company through its subsidiary is developing cellular therapeutics to treat diseases.
本社所在地 106 Allen Road Fourth Floor Basking Ridge NJ 07920 USA
代表者氏名 David J. Mazzo デビットJ.マッツォ
代表者役職名 Chief Executive Officer Independent Director
電話番号 +1 908-842-0100
設立年月日 29465
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 221人
url https://www.caladrius.com/
nasdaq_url https://www.nasdaq.com/symbol/clbs
adr_tso
EBITDA EBITDA(百万ドル) -22.53046
終値(lastsale) 5.01
時価総額(marketcap) 48724464.42
時価総額 時価総額(百万ドル) 44.34802
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -5.95137
当期純利益 当期純利益(百万ドル) 13.58047
決算概要 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Caladrius Biosciences Inc revenues was not reported. Net loss before extraordinary items increased 5% to $9.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.95.

 CLBSのテクニカル分析


 CLBSのニュース

   Caladrius Biosciences (CLBS) Investor Presentation - Slideshow  2019-05-01
The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with this Read more …
   BTE, BRSS, WVE and FLXN among notable midday movers  2019-04-10
Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal…
   Caladrius Biosciences, Inc. 2018 Q3 - Results - Earnings Call Slides  2018-11-12
The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with their 2018 Q3 earnings Read more …
   Healthcare and Tech tops midday movers  2018-11-12
More news on: Apptio, OPKO Health, Inc., Globus Maritime Ltd., Stocks on the move, , Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カラドリアス・バイオサイエンス CLBS Caladrius Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)